SMMT

Summit Therapeutics

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 2

Sell signal 1

stock price surged significantly

consensus rating "Buy"

RSI Overbought

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About SMMT

Summit Therapeutics Inc.

An UK developer of novel medicines for the treatment of Clostridium difficile infection

Industry

Pharmaceutical

Established Date

11/22/2013

Listing Date

03/05/2015

Exchange

NASDAQ Stock Exchange

Full-time Employees

159

Fiscal Year Ends

12-31

Website

www.smmttx.com

Security Type

Common stock

Office address

601 Brickell Key Drive, Suite 1000, Miami, FL 33131

Business

Introduction

Summit Therapeutics Inc., a Delaware corporation (" New Summit "), was incorporated in England and Wales on November 22, 2013 and has become a follow-on issuer to the Company. The Company is a biopharmaceutical company focused on the discovery, development and commercialization of patient, physician, caregiver and socially friendly drug therapies designed to improve quality of life, extend potential lifespan, and address serious unmet medical needs. The company's pipeline of product candidates is designed to be patient-friendly, new-age standard of care in the field of oncology therapy.

Company Financials

EPS

SMMT has released its 2024 Q4 earnings. EPS was reported at -0.07, versus the expected -0.08, beating expectations. The chart below visualizes how SMMT has performed over recent quarters, highlighting trends in earnings surprises.